United States Biotechnology & Medical Research

Alder Biopharmaceuticals Inc (ALDR)

Track

Ticker: ALDR Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Buy 22 Oct 2019
Value US$893,752.21 | Price 183.45 | Shares 98,082
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2019-10-24 2019-10-22 B Purchase
H LUNDBECK A S
Large shareholder
98,082
183.45
US$893,752 		98,082 183.45 US$893,752
2019-09-18 2019-09-16 PlS Planned sale
2.5
Smith Jeffrey T L

Managing Director
2,591 -10.2%
98.42
US$2,476,179 		2,591 -10.2% 98.42 US$2,476,179
2019-04-25 2019-04-25 PlS Planned sale
Benedict Larry

EVP and PAO
65,445 -40.1%
25.03
US$4,476,064 		65,445 -40.1% 25.03 US$4,476,064
2019-04-25 2019-04-25 PlS Planned sale
Lavelle Erin

Chief Operating Officer
1,434 -24.5%
13.67
US$19,599 		1,434 -24.5% 13.67 US$19,599
2019-04-25 2019-04-25 PlS Planned sale
Hassler Randal

EVP, Pharmaceutical Ops.
1,738 -24.2%
13.85
US$24,067 		1,738 -24.2% 13.85 US$24,067
2019-04-25 2019-04-25 PlS Planned sale
Bucher James B

EVP & General Counsel
1,897 -16.2%
13.85
US$26,281 		1,897 -16.2% 13.85 US$26,281
2018-12-04 2018-12-03 PlS Planned sale Smith Jeffrey T L

Managing Director

Officer
5,044 -85.9%
13.84
US$69,826 		5,044 -85.9% 13.84 US$69,826
2018-11-05 2018-11-01 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
1,319 -0.5%
13.78
US$18,170 		1,319 -0.5% 13.78 US$18,170
2018-11-05 2018-11-01 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
23,683 -8.8%
13.40
US$317,419 		23,683 -8.8% 13.40 US$317,419
2018-11-05 2018-11-01 PlS Planned sale Smith Jeffrey T L

Managing Director

Officer
5,040 -85.8%
13.42
US$67,637 		5,040 -85.8% 13.42 US$67,637
2018-10-03 2018-10-01 PlS Planned sale Smith Jeffrey T L

Managing Director

Officer
2,000 -70.6%
15.97
US$31,944 		2,000 -70.6% 15.97 US$31,944
2018-10-03 2018-10-01 PlS Planned sale Smith Jeffrey T L

Managing Director

Officer
3,040 -51.8%
15.26
US$46,385 		3,040 -51.8% 15.26 US$46,385
2018-10-03 2018-10-01 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
6,554 -2.6%
15.97
US$104,692 		6,554 -2.6% 15.97 US$104,692
2018-10-03 2018-10-01 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
18,445 -6.9%
15.25
US$281,314 		18,445 -6.9% 15.25 US$281,314
2018-09-06 2018-09-04 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
24,999 -9.3%
17.99
US$449,680 		24,999 -9.3% 17.99 US$449,680
2018-09-06 2018-09-04 PlS Planned sale Smith Jeffrey T L

Managing Director

Officer
5,040 -85.8%
18.00
US$90,699 		5,040 -85.8% 18.00 US$90,699
2018-08-02 2018-08-01 PlS Planned sale Smith Jeffrey T L

Managing Director

Officer
980 -54.1%
19.76
US$19,369 		980 -54.1% 19.76 US$19,369
2018-08-02 2018-08-01 PlS Planned sale Smith Jeffrey T L

Managing Director

Officer
4,060 -69.2%
19.49
US$79,120 		4,060 -69.2% 19.49 US$79,120
2018-08-02 2018-08-01 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
24,999 -9.3%
19.55
US$488,768 		24,999 -9.3% 19.55 US$488,768
2018-07-03 2018-07-02 PlS Planned sale Smith Jeffrey T L

Managing Director

Officer
12,161 -93.6%
15.49
US$188,364 		12,161 -93.6% 15.49 US$188,364
2018-07-03 2018-07-02 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
24,999 -9.3%
15.48
US$387,002 		24,999 -9.3% 15.48 US$387,002
2018-06-05 2018-06-01 PlS Planned sale Litton Mark James

Chief Business Officer

Officer
4,474 -4.2%
18.24
US$81,587 		4,474 -4.2% 18.24 US$81,587
2018-06-05 2018-06-01 PlS Planned sale Litton Mark James

Chief Business Officer

Officer
18,253 -14.6%
17.74
US$323,825 		18,253 -14.6% 17.74 US$323,825
2018-06-05 2018-06-01 PlS Planned sale Smith Jeffrey T L

Managing Director

Officer
1,100 -57.0%
18.29
US$20,115 		1,100 -57.0% 18.29 US$20,115
2018-06-05 2018-06-01 PlS Planned sale Smith Jeffrey T L

Managing Director

Officer
11,061 -85.1%
17.81
US$197,012 		11,061 -85.1% 17.81 US$197,012
2018-06-05 2018-06-01 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
4,799 -1.9%
18.25
US$87,562 		4,799 -1.9% 18.25 US$87,562
2018-06-05 2018-06-01 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
20,200 -7.5%
17.76
US$358,794 		20,200 -7.5% 17.76 US$358,794
2018-05-18 2018-05-16 PlS Planned sale Smith Jeffrey T L

Managing Director

Officer
12,161 -93.6%
15.03
US$182,758 		12,161 -93.6% 15.03 US$182,758
2017-11-15 2017-11-13 PlS Planned sale Litton Mark James

Chief Business Officer
16,519 -14.2%
10.80
US$178,486 		16,519 -14.2% 10.80 US$178,486
2017-10-18 2017-10-16 PlS Planned sale Litton Mark James

Chief Business Officer
16,520 -14.2%
12.33
US$203,703 		16,520 -14.2% 12.33 US$203,703
2017-07-18 2017-07-18 B Purchase YARNO WENDY L Non-Executive Director
5,000 +inf%
10.00
US$50,000 		5,000 +inf% 10.00 US$50,000
2017-07-18 2017-07-18 B Purchase DOW STEPHEN M Non-Executive Director
25,000 +8.9%
10.00
US$250,000 		25,000 +8.9% 10.00 US$250,000
2017-06-22 2017-06-20 PlS Planned sale Smith Jeffrey T L

Sr. VP Translational Medicine
585 -41.3%
20.00
US$11,700 		585 -41.3% 20.00 US$11,700
2017-02-13 2017-02-09 PlS Planned sale Schatzman Randall C

President and CEO

Executive Director
30,000 -20.7%
25.03
US$750,756 		30,000 -20.7% 25.03 US$750,756
2017-01-20 2017-01-18 PlS Planned sale Litton Mark James

Chief Business Officer
1,498 -1.5%
23.10
US$34,599 		1,498 -1.5% 23.10 US$34,599
2017-01-09 2017-01-09 PlS Planned sale Litton Mark James

Chief Business Officer
500 -0.5%
23.00
US$11,500 		500 -0.5% 23.00 US$11,500
2017-01-09 2017-01-06 PlS Planned sale Litton Mark James

Chief Business Officer
6,800 -6.4%
23.02
US$156,520 		6,800 -6.4% 23.02 US$156,520
2017-01-09 2017-01-05 PlS Planned sale Litton Mark James

Chief Business Officer
2,216 -2.2%
23.00
US$50,972 		2,216 -2.2% 23.00 US$50,972
2016-12-05 2016-12-01 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
500 -0.2%
23.62
US$11,810 		500 -0.2% 23.62 US$11,810
2016-12-05 2016-12-01 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
3,136 -1.3%
22.64
US$71,002 		3,136 -1.3% 22.64 US$71,002
2016-12-05 2016-12-01 PlS Planned sale Smith Jeffrey T L

Sr. VP Translational Medicine

Officer
500 -37.6%
23.62
US$11,810 		500 -37.6% 23.62 US$11,810
2016-12-05 2016-12-01 PlS Planned sale Smith Jeffrey T L

Sr. VP Translational Medicine

Officer
2,500 -65.3%
22.61
US$56,518 		2,500 -65.3% 22.61 US$56,518
2016-11-14 2016-11-09 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
10,000 -4.0%
30.18
US$301,839 		10,000 -4.0% 30.18 US$301,839
2016-11-09 2016-11-07 PlS Planned sale Schatzman Randall C

President and CEO

Executive Director
10,000 -8.0%
25.16
US$251,605 		10,000 -8.0% 25.16 US$251,605
2016-11-03 2016-11-01 PlS Planned sale Smith Jeffrey T L

Sr. VP Translational Medicine

Officer
400 -100.0%
24.88
US$9,950 		400 -100.0% 24.88 US$9,950
2016-11-03 2016-11-01 PlS Planned sale Smith Jeffrey T L

Sr. VP Translational Medicine

Officer
2,600 -86.7%
24.26
US$63,082 		2,600 -86.7% 24.26 US$63,082
2016-10-19 2016-10-17 PlS Planned sale Litton Mark James

Chief Business Officer

Officer
2,000 -7.1%
27.50
US$55,000 		2,000 -7.1% 27.50 US$55,000
2016-10-19 2016-10-17 PlS Planned sale Litton Mark James

Chief Business Officer

Officer
2,000 -7.1%
27.50
US$55,005 		2,000 -7.1% 27.50 US$55,005
2016-10-19 2016-10-17 PlS Planned sale Litton Mark James

Chief Business Officer

Officer
2,000 -7.1%
27.50
US$54,993 		2,000 -7.1% 27.50 US$54,993
2016-10-05 2016-10-03 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
6,249 -2.5%
31.51
US$196,888 		6,249 -2.5% 31.51 US$196,888
2016-10-05 2016-10-03 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
3,751 -1.5%
31.00
US$116,263 		3,751 -1.5% 31.00 US$116,263
2016-10-05 2016-10-03 PlS Planned sale Smith Jeffrey T L

Sr. VP Translational Medicine

Officer
702 -100.0%
31.62
US$22,199 		702 -100.0% 31.62 US$22,199
2016-10-05 2016-10-03 PlS Planned sale Smith Jeffrey T L

Sr. VP Translational Medicine

Officer
2,298 -76.6%
30.99
US$71,216 		2,298 -76.6% 30.99 US$71,216
2016-10-05 2016-10-03 PlS Planned sale Schatzman Randall C

President and CEO

Executive Director
2,700 -2.3%
31.55
US$85,189 		2,700 -2.3% 31.55 US$85,189
2016-10-05 2016-10-03 PlS Planned sale Schatzman Randall C

President and CEO

Executive Director
5,481 -4.5%
30.95
US$169,622 		5,481 -4.5% 30.95 US$169,622
2016-09-06 2016-09-01 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
10,000 -4.0%
32.49
US$324,949 		10,000 -4.0% 32.49 US$324,949
2016-09-06 2016-09-01 PlS Planned sale Schatzman Randall C

President and CEO

Executive Director
10,000 -8.0%
32.48
US$324,820 		10,000 -8.0% 32.48 US$324,820
2016-09-06 2016-09-01 PlS Planned sale Smith Jeffrey T L

Sr. VP Translational Medicine

Officer
100 -100.0%
33.10
US$3,310 		100 -100.0% 33.10 US$3,310
2016-09-06 2016-09-01 PlS Planned sale Smith Jeffrey T L

Sr. VP Translational Medicine

Officer
2,900 -96.7%
32.47
US$94,173 		2,900 -96.7% 32.47 US$94,173
2016-08-17 2016-08-15 S Sale Smith Jeffrey T L

Sr. VP Translational Medicine

Officer
3,000 -100.0%
31.17
US$93,512 		3,000 -100.0% 31.17 US$93,512
2016-08-03 2016-08-01 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
32 -0.0%
32.54
US$1,041 		32 -0.0% 32.54 US$1,041
2016-08-03 2016-08-01 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
6,394 -2.5%
30.88
US$197,423 		6,394 -2.5% 30.88 US$197,423
2016-08-03 2016-08-01 PlS Planned sale Schatzman Randall C

President and CEO

Executive Director
16 -0.0%
32.69
US$523 		16 -0.0% 32.69 US$523
2016-08-03 2016-08-01 PlS Planned sale Schatzman Randall C

President and CEO

Executive Director
4,816 -4.0%
31.68
US$152,570 		4,816 -4.0% 31.68 US$152,570
2016-08-03 2016-08-01 PlS Planned sale Schatzman Randall C

President and CEO

Executive Director
5,168 -4.1%
30.65
US$158,420 		5,168 -4.1% 30.65 US$158,420
2016-07-28 2016-07-27 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
9,187 -3.7%
30.15
US$277,023 		9,187 -3.7% 30.15 US$277,023
2016-07-28 2016-07-26 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
813 -0.3%
30.00
US$24,392 		813 -0.3% 30.00 US$24,392
2016-07-27 2016-07-25 PlS Planned sale Schatzman Randall C

President and CEO

Executive Director
10,000 -8.0%
28.08
US$280,805 		10,000 -8.0% 28.08 US$280,805
2016-06-15 2016-06-13 PlS Planned sale Litton Mark James

Chief Business Officer

Officer
200 -0.7%
29.64
US$5,928 		200 -0.7% 29.64 US$5,928
2016-06-15 2016-06-13 PlS Planned sale Litton Mark James

Chief Business Officer

Officer
1,800 -6.0%
28.90
US$52,012 		1,800 -6.0% 28.90 US$52,012
2016-06-15 2016-06-13 PlS Planned sale Litton Mark James

Chief Business Officer

Officer
100 -0.4%
29.60
US$2,960 		100 -0.4% 29.60 US$2,960
2016-06-15 2016-06-13 PlS Planned sale Litton Mark James

Chief Business Officer

Officer
1,900 -6.3%
28.89
US$54,900 		1,900 -6.3% 28.89 US$54,900
2016-06-15 2016-06-13 PlS Planned sale Litton Mark James

Chief Business Officer

Officer
100 -0.4%
29.60
US$2,960 		100 -0.4% 29.60 US$2,960
2016-06-15 2016-06-13 PlS Planned sale Litton Mark James

Chief Business Officer

Officer
1,900 -6.3%
28.90
US$54,903 		1,900 -6.3% 28.90 US$54,903
2016-06-07 2016-06-03 S Sale Smith Jeffrey T L

Sr. VP Translational Medicine

Officer
1,000 -100.0%
31.83
US$31,827 		1,000 -100.0% 31.83 US$31,827
Explore more

More insider trading research around Alder Biopharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America